GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » BioCorRx Inc (OTCPK:BICX) » Definitions » Beneish M-Score

BioCorRx (BioCorRx) Beneish M-Score

: -25.33 (As of Today)
View and export this data going back to 2009. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -25.33 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for BioCorRx's Beneish M-Score or its related term are showing as below:

BICX' s Beneish M-Score Range Over the Past 10 Years
Min: -161.21   Med: -12.64   Max: 26.15
Current: -25.33

During the past 13 years, the highest Beneish M-Score of BioCorRx was 26.15. The lowest was -161.21. And the median was -12.64.


BioCorRx Beneish M-Score Historical Data

The historical data trend for BioCorRx's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCorRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.15 -4.32 -13.66 -11.62 -25.33

BioCorRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.62 -17.13 -11.81 -19.18 -25.33

Competitive Comparison

For the Medical Care Facilities subindustry, BioCorRx's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCorRx Beneish M-Score Distribution

For the Healthcare Providers & Services industry and Healthcare sector, BioCorRx's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where BioCorRx's Beneish M-Score falls into.



BioCorRx Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of BioCorRx for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1153+0.528 * 1.5537+0.404 * 1.0337+0.892 * 0.4159+0.115 * 0.5078
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 2.0272+4.679 * -4.719794-0.327 * 2.2858
=-25.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.08 Mil.
Revenue was 0.019 + 0.01 + 0.02 + 0.04 = $0.09 Mil.
Gross Profit was 0.006 + 0.006 + 0.009 + 0.032 = $0.05 Mil.
Total Current Assets was $0.19 Mil.
Total Assets was $0.39 Mil.
Property, Plant and Equipment(Net PPE) was $0.15 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.20 Mil.
Selling, General, & Admin. Expense(SGA) was $2.88 Mil.
Total Current Liabilities was $6.43 Mil.
Long-Term Debt & Capital Lease Obligation was $0.08 Mil.
Net Income was -0.969 + -0.866 + -0.922 + -1.01 = $-3.77 Mil.
Non Operating Income was 0.005 + 0 + -0.034 + -0.048 = $-0.08 Mil.
Cash Flow from Operations was -0.534 + -0.351 + -0.572 + -0.397 = $-1.85 Mil.
Total Receivables was $0.17 Mil.
Revenue was 0.083 + 0.094 + 0.016 + 0.021 = $0.21 Mil.
Gross Profit was 0.074 + 0.092 + 0.013 + 0.019 = $0.20 Mil.
Total Current Assets was $0.32 Mil.
Total Assets was $0.77 Mil.
Property, Plant and Equipment(Net PPE) was $0.35 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.14 Mil.
Selling, General, & Admin. Expense(SGA) was $3.41 Mil.
Total Current Liabilities was $5.36 Mil.
Long-Term Debt & Capital Lease Obligation was $0.26 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.077 / 0.089) / (0.166 / 0.214)
=0.865169 / 0.775701
=1.1153

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.198 / 0.214) / (0.053 / 0.089)
=0.925234 / 0.595506
=1.5537

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.187 + 0.148) / 0.389) / (1 - (0.317 + 0.347) / 0.767)
=0.138817 / 0.134289
=1.0337

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.089 / 0.214
=0.4159

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.143 / (0.143 + 0.347)) / (0.2 / (0.2 + 0.148))
=0.291837 / 0.574713
=0.5078

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2.875 / 0.089) / (3.41 / 0.214)
=32.303371 / 15.934579
=2.0272

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.083 + 6.431) / 0.389) / ((0.255 + 5.364) / 0.767)
=16.745501 / 7.325945
=2.2858

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-3.767 - -0.077 - -1.854) / 0.389
=-4.719794

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

BioCorRx has a M-score of -25.33 suggests that the company is unlikely to be a manipulator.


BioCorRx Beneish M-Score Related Terms

Thank you for viewing the detailed overview of BioCorRx's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCorRx (BioCorRx) Business Description

Traded in Other Exchanges
N/A
Address
2390 East Orangewood Avenue, Suite 500, Anaheim, CA, USA, 92806
BioCorRx Inc through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders. The BioCorRx Recovery Program is a non-addictive, medication-assisted treatment program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application.
Executives
Louis C. Lucido director 2390 EAST ORANGEWOOD AVENUE, SUITE 500, ANAHEIM CA 92806
Joseph J Galligan director, 10 percent owner 333 SOUTH GRAND AVENUE, 18TH FLOOR, LOS ANGELES CA 90071
Harsha Murthy director 5209 38TH STREET,NW, WASHINGTON DC 20015
Luisa Ingargiola director 4826 BLUE JAY CIRCLE, PALM HARBOR FL 34683
Thomas Patrick Welch officer: Vice President of Operations 10453 SARAH ST., TOLUCA LAKE CA 91602
Kent Emry director, officer: Chief Executive Officer 2390 EAST ORANGEWOOD AVENUE, SUITE 500, ANAHEIM CA 92806
Brady James Granier director 13024 DELANO STREET, VALLEY GLEN CA 91401
Lourdes Felix director, officer: Chief Financial Officer 15 CALLE VERANO, RANCHO SANTA MARGARITA CA 92688
Jorge Jr Andrade director, officer: Chief Executive Officer PO BOX 5366, SANTA ANA CA 92704
Muller Neil Terrence Mr director, officer: President 13231 SANDHURST PLACE, SANTA ANA CA 92705

BioCorRx (BioCorRx) Headlines

From GuruFocus

BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors

By Stock market mentor Stock market mentor 01-24-2023

BioCorRx Business Update for the First Quarter of 2022

By GuruFocusNews GuruFocusNews 06-26-2022

BioCorRx Business Update for the First Quarter of 2022

By GuruFocusNews GuruFocusNews 07-06-2022

BioCorRx to Present at the LD Micro Invitational XII on June 7th

By GuruFocusNews GuruFocusNews 06-20-2022